Biontech Small Molecules Deal History & Licensing Activity
Biontech Small Molecules is a biotech headquartered in Sweden. Over the past three years, Biontech Small Molecules has been involved in 5 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (4 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Bispecific Antibodies
Focus Area
Option Deals
Biontech Small Molecules Pipeline Focus
Therapeutic areas and modalities where Biontech Small Molecules is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Biontech Small Molecules Strategic Signals
Key indicators of Biontech Small Molecules's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Biontech Small Molecules's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Option Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Biontech Small Molecules Licensing & Deal Activity
Biontech Small Molecules is a biotech company based in Sweden that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Biontech Small Molecules ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Biontech Small Molecules include Option Deals (4 deals and trials), and Women's Health (1 deal and trial). In terms of modality, Biontech Small Molecules has shown particular interest in bispecific antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Biontech Small Molecules and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Biontech Small Molecules's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.